Stockscreener 앱 받기
746.54
0.94%
6.97
전일 마감가:
$739.57
열려 있는:
$737.2
하루 거래량:
465.99K
Relative Volume:
0.63
시가총액:
$76.86B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
18.19
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
+1.54%
1개월 성능:
-7.57%
6개월 성능:
-2.78%
1년 성능:
+30.99%
1일 변동 폭
$732.83
$751.27
1주일 범위
$722.02
$753.68
52주 변동 폭
$541.00
$859.34
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 업그레이드 | Argus | Hold → Buy |
| 2026-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2026-05-18 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD - Zacks Investment Research
REGN Maintains Buy Rating -- Price Target Raised to $780 by Trui - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Regeneron stock gains 1.17 percent as oncology data advances - AD HOC NEWS
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN) - Yahoo! Finance Canada
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 - Investing News Network
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Regeneron sees nearly $0.18 per share earnings headwind (REGN) - Seeking Alpha
Regeneron to Present Late-Breaking ESMO 2026 Data on Libtayo in High-Risk CSCC and Cancer-Associated Thrombosis - Quiver Quantitative
Argus upgrades Regeneron stock to Buy with USD 850.00 target - ad-hoc-news.de
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion - simplywall.st
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion - simplywall.st
Regeneron: The Easy Money Has Been Made (Rating Downgrade) (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion - simplywall.st
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion - Simply Wall Street
Regeneron Pharmaceuticals, Inc. (REGN) Stock forecasts - Yahoo Finance UK
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial DataRegeneron Pharmaceuticals - Benzinga
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870 - Yahoo Finance
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology AntibodiesSlideshow (NASDAQ:REGN) 2026-10-01 - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - BioSpace
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - Reuters
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone - TipRanks
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Strong-Buy at Zacks Research - MarketBeat
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18 - MarketBeat
What Is Regeneron Pharmaceuticals (REGN) Facing After A Rival Matched Its Key Eye Drug? - simplywall.st
REGN or ILMN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
RBC Capital reiterates Regeneron stock rating on JV survey results - Investing.com
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Zacks Investment Research
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCourt Marion | Officer |
Sep 03 '26 |
Proposed Sale |
857.00 |
1,131 |
969,267 |
0 |
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Proposed Sale |
850.00 |
400 |
340,000 |
0 |
| McCourt Marion | Officer |
Sep 02 '26 |
Proposed Sale |
850.00 |
1,215 |
1,032,750 |
0 |
| LAROSA JOSEPH J | EVP General Counsel and Secret |
Aug 19 '26 |
Option Exercise |
381.92 |
12,282 |
4,690,741 |
45,392 |
| Fenimore Christopher R. | EVP Finance CFO |
Aug 18 '26 |
Option Exercise |
381.92 |
6,283 |
2,399,603 |
24,583 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Sale |
800.00 |
800 |
640,000 |
1,703 |
| Guarini Kathryn | Director |
Aug 10 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
14.21%
자본화:
|
볼륨(24시간):